Skip to main content

Advertisement

Table 1 Clinicopathologic characteristics of patients

From: Metabolic phenotypes in primary unknown metastatic carcinoma

Clinical parameters Total N = 77 (%) Histologic subtype p-value
AD (n = 27) (%) PD (n = 16) (%) SQ (n = 20) (%) UD (n = 14) (%)
Age (years, mean ± SD) 55.4 ± 11.8 59.3 ± 12.3 55.3 ± 12.1 55.0 ± 9.6 48.3 ± 10.6 0.042
Sex       0.521
 Female 29 (37.7) 13 (48.1) 6 (37.5) 6 (30.0) 4 (28.6)  
 Male 48 (62.3) 14 (51.9) 10 (62.5) 14 (70.0) 10 (71.4)  
Clinical subtype       <0.001
 Nodal type 34 (44.2) 3 (11.1) 8 (50.0) 14 (70.0) 9 (64.3)  
 Single organ type 15 (19.5) 6 (22.2) 5 (31.3) 0 (0.0) 4 (28.6)  
 Intermediate type 14 (18.2) 7 (25.9) 1 (6.3) 5 (25.0) 1 (7.1)  
 Carcinomatosis type 14 (18.2) 11 (40.7) 2 (12.5) 1 (5.0) 0 (0.0)  
Organs involved       0.102
 Lymph node 49 (63.6) 12 (44.4) 9 (56.3) 19 (95.0) 9 (64.3)  
 Bone 10 (13.0) 6 (22.2) 2 (12.5) 0 (0.0) 2 (14.3)  
 Brain 9 (11.7) 4 (14.8) 2 (12.5) 1 (5.0) 2 (14.3)  
 Other 9 (11.7) 5 (18.5) 3 (18.8) 0 (0.0) 1 (7.1)  
Postoperative treatment       0.039
 None 21 (27.3) 8 (29.6) 3 (18.8) 4 (20.0) 6 (42.9)  
 Chemotherapy 24 (31.2) 12 (44.4) 5 (31.3) 3 (15.0) 4 (28.6)  
 Radiation therapy 15 (19.5) 6 (22.2) 1 (6.3) 6 (30.0) 2 (14.3)  
 Chemo-radiation therapy 17 (22.1) 1 (3.7) 7 (43.8) 7 (35.0) 2 (14.3)  
  1. PD: poorly differentiated carcinoma, AD: adenocarcinoma, SQ: squamous cell carcinoma, UD: undifferentiated carcinoma.
  2. Bold represents p<0.05.